Beryl Capital Management LLC Makes New Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Beryl Capital Management LLC bought a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 5,935,009 shares of the biopharmaceutical company’s stock, valued at approximately $18,042,000. Revance Therapeutics makes up 4.1% of Beryl Capital Management LLC’s holdings, making the stock its 3rd largest position. Beryl Capital Management LLC owned 0.06% of Revance Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Natixis purchased a new stake in Revance Therapeutics in the fourth quarter worth about $31,000. Two Sigma Securities LLC purchased a new stake in shares of Revance Therapeutics in the 4th quarter worth approximately $35,000. Alpine Global Management LLC bought a new position in Revance Therapeutics during the 4th quarter valued at approximately $37,000. RPO LLC purchased a new position in Revance Therapeutics during the fourth quarter valued at $55,000. Finally, Virtu Financial LLC bought a new stake in Revance Therapeutics in the third quarter worth $120,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Friday. The business has a 50-day simple moving average of $3.65 and a two-hundred day simple moving average of $3.80. The firm has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $6.65.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. StockNews.com assumed coverage on shares of Revance Therapeutics in a report on Sunday, April 27th. They issued a “hold” rating for the company. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.